Skip to main content
. 2022 Nov 8;13:1023558. doi: 10.3389/fimmu.2022.1023558

Figure 5.

Figure 5

Analysis of the interactions between the respective Toll-Like Receptors and multi-epitope vaccine constructs (A) The crystalline structure of the first multi-epitope vaccine construct docked with TLR2. The multi-epitope chain is shown in red and the TLR2 in blue. (B) The crystalline structure of the second multi-epitope vaccine construct docked with TLR4. The multi-epitope chain is shown in red and the TLR4 in blue. (C) The solubility and aggregation propensity model of the first docked complex. The graphical representation model shows the soluble residues in red, the aggregation-prone residues in blue, and residues with no predicted influence shown in white. (D) The solubility and aggregation propensity model of the second docked complex. The graphical representation model shows the soluble residues in red, the aggregation-prone residues in blue, and residues with no predicted influence shown in white.